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Ischemia reperfusion injury (IRI) leads to significant tissue damage in liver surgery. Polyethylene glycols (PEGs) are water
soluble nontoxic polymers that have proved their effectiveness against IRI. The objective of our study was to investigate the
potential protective effects of intravenous administration of a high molecular weight PEG of 35 kDa (PEG 35) in steatotic livers
subjected to cold ischemia reperfusion. In this study, we used isolated perfused rat liver model to assess the effects of PEG 35
intravenous administration after prolonged cold ischemia (24 h, 4∘C) and after reperfusion (2 h, 37∘C). Liver injury was measured
by transaminases levels and mitochondrial damage was determined by confocal microscopy assessing mitochondrial polarization
(after cold storage) and by measuring glutamate dehydrogenase activity (after reperfusion). Also, cell signaling pathways involved
in the physiopathology of IRI were assessed by western blot technique. Our results show that intravenous administration of PEG
35 at 10mg/kg ameliorated liver injury and protected the mitochondria. Moreover, PEG 35 administration induced a significant
phosphorylation of prosurvival protein kinase B (Akt) and activation of cytoprotective factors e-NOS and AMPK. In conclusion,
intravenous PEG 35 efficiently protects steatotic livers exposed to cold IRI.
1. Introduction
Organ preservation is a fundamental requirement in organ
transplantation; it preserves the viability of the organ during
its transport from the donor to the recipient so that the graft
can maintain its function after transplantation [1]. Besides
advances in organ preservation, the presence of steatosis
remains a limiting factor for the suitable preservation of
liver grafts, as steatotic livers are particularly vulnerable to
hepatic ischemia reperfusion injury (IRI) [2]. Their use is
accompanied by increased risk of primary failure and lowered
success of liver transplantation [3]. Currently, the increasing
needs of transplantation as well as the scarce of donors pool
have obliged the physicians to take advantage of suboptimal
liver grafts, as steatotic ones [4]. For this reason, there is an
urgent need to explore new strategies that provide a more
efficient preservation of steatotic liver grafts. Minimizing
the deleterious effects of hypothermia could decrease the
reperfusion injury and, consequently, assure an increased rate
of graft survival after transplantation.
Polyethylene glycols (PEGs) are water soluble nontoxic
polymers that have been employed in many biomedical
applications such as gastrointestinal disorders and drugs
pegylation [5, 6]. Besides their usefulness as oncotic agents
in preservation solutions [7, 8], it has been shown that
PEGs molecules protect against cold injury and ischemic
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damage. Indeed, PEG used as cryoprotectant in supercooling
techniquewas necessary to achieve successful liver transplan-
tation [9]. Moreover, PEG suppressed hypothermic-induced
cell swelling in hepatocyte preservation [10] and protected
primary hepatocyte during supercooling preservation [11].
Also, PEG protected cardiac myocytes from hypoxia and
reoxygenation-induced cell death [12], decreased oxidative
stress [13], and protected injured mitochondria [14].
With this in mind, we hypothesized whether intravenous
administration of PEG in the rat prior to organ procure-
ment could protect fatty liver graft against hypothermic
and hypoxic damage occurring during preservation and the
subsequent reperfusion injury. Our results demonstrated that
PEG 35 prevented the deleterious effects of cold IRI when
administered intravenously in obese rats.
2. Materials and Methods
2.1. Animals. Male homozygous obese Zucker rats, aged 9 to
10 weeks, were purchased from Charles River (France) and
housed at 22∘C with free access to water and standard chow.
All experiments were approved by the Ethics Committees for
Animal Experimentation (CEEA, Directive 697/14), Univer-
sity of Barcelona, and were conducted according to European
Union regulations for animal experiments (Directive 86/609
CEE).
2.2. Liver Procurement and Ex Vivo Perfusion. All procedures
were performed under isoflurane anesthesia inhalation. After
laparotomy, the common bile duct was cannulated and livers
were flushed with 40mL of chilled UWpreservation solution
(4∘C) by the mean of catheter insertion into the aorta. After
cooling, a second catheter was inserted into the portal vein
to complete liver rinsing with further 10mL of UW solution.
The whole liver was then excised and preserved at 4∘C for
24 h in the same solution. This procedure implicates the
death of the animal under isoflurane anesthesia, and thus
the application of analgesia or euthanasia was unnecessary.
After 24 h of cold preservation, steatotic livers were removed
from preserved solution and flushed at room temperature
with 20mL of Ringer Lactate solution to eliminate the
metabolite waste accumulated during liver storage. Then,
livers were perfused at 37∘C via the portal vein in a closed
and controlled pressure circuit. Time point 0 was considered
when the portal catheter was satisfactorily connected to
the circuit. During the first 15 minutes of perfusion (initial
equilibration period), the flow was progressively increased in
order to stabilize the portal pressure at 12mmHg (Pression
Monitor BP-1; Pression Instruments, Sarasota, FL). The flow
was controlled by a peristaltic pump (Minipuls 3; Gilson,
France). The reperfusion liquid (150mL for each perfusion)
consisted of a cell culture medium (William’s medium E;
BioWhittaker, Barcelona, Spain) with a Krebs-Henseleit-like
electrolyte composition enriched with 5% albumin as oncotic
supply. The medium was continuously gassed with 95% O
2
and 5% CO2 gas mixture and subsequently passed through
a heat exchanger (37∘C) and a bubble trap prior to entering
the liver. After 120 minutes of normothermic reperfusion,
the effluent perfusion fluid was collected for biochemical
determinations and hepatic tissues were sampled and stored
at −80∘C for further analysis.
2.3. Drug Treatment. PEG 35 was kindly provided by IGL-1
Company. PEG 35 was dissolved in physiological saline
(5 g/L) and administrated 10min before liver procurement by
intravenous bolus through the penile vein at the concentra-
tion of 10mg/kg.
For confocal microscopy study with PEG-FITC, PEG 35
was fused with fluorescein as previously described byMero et
al. [15].
2.4. Experimental Groups. All animals were randomly dis-
tributed into different experimental groups, as indicated
below (Scheme 1).
Protocol 1: Effect of PEG 35 in Fatty Livers after Cold Storage.
In order to study the effects of PEG 35 administration in cold
preservation, rats were randomly divided into the following
groups:
(1) Group 1: Control 1 (Ctr 1) (𝑛 = 4): control livers
were flushed via the portal vein with Ringer’s lactate
solution immediately after laparotomy. Then liver
samples were collected for posterior analysis.
(2) Group 2 (𝑛 = 6): UW: steatotic livers were preserved
for 24 hours in UW solution at 4∘C.Then, livers were
flushed with Ringer’s solution and the effluent liquid
was collected for further biochemical determinations.
Liver tissue was stored at −80∘C.
(3) Group 3 (𝑛 = 6): PEG 35: livers were pretreated with
PEG 35 intravenously at 10mg/kg 10min before liver
procurement and then preserved for 24 hours in UW
solution as in group 2.
Protocol 2: Effect of PEG 35 in Fatty Livers after 24 h of Cold
Storage and 2 h of Normothermic Reperfusion. To examine the
effect of PEG 35 in liver injury after normothermic perfusion,
fatty livers were randomized in the following groups:
(1) Control group (Ctr 2) (𝑛 = 4): after procurement,
steatotic livers were ex vivo perfused for 2 h at 37∘C
as described above, without prior cold storage.
(2) UW group (𝑛 = 6): fatty livers were preserved in UW
preservation solution for 24 hours at 4∘C and then
subjected to 2 h of normothermic reperfusion at 37∘C.
(3) PEG 35 group (𝑛 = 6): Zucker Ob rats were pretreat-
ed with intravenous administration of PEG 35 at
10mg/kg, 10min before liver procurement. Then,
livers were preserved for 24 h in UW solution and
finally ex vivo perfused for 2 hours at 37∘C.
2.5. Liver Injury: Transaminases Assay. Hepatic injury was
assessed in terms of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels with commercial
kits from RAL (Barcelona, Spain). Briefly, 100 𝜇L of effluent
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Scheme 1: Experimental designs to investigate PEG 35 effects on steatotic livers after cold ischemia at 4∘C (Protocol 1) and after cold storage
followed by normothermic ex vivo reperfusion (Protocol 2).
washout liquid or perfusatewas added to 1mLof the substrate
provided by the commercial kit and then transaminases
activity was measured at 340 nm with a UV spectrometer
and calculated following the supplier’s instructions. Results
were normalized using a commercial calibrator (Biocal, RAL,
Barcelona, Spain).
2.6. Mitochondrial Damage
2.6.1. Glutamate Dehydrogenase Activity. Glutamate dehy-
drogenase (GLDH) is a mitochondrial enzyme present pre-
dominantly in liver and contributes to the oxidative deami-
nation of glutamate. Measurable increases in serum levels are
indicative of mitochondrial damage. Serum concentrations
of GLDH were determined using a commercial kit (GLDH,
Randox laboratories Ltd., Crumlin, UK) by quantifying the
decrease in absorbance at 340 nm according to the manufac-
turer’s protocol.
2.6.2. ConfocalMicroscopy. After 24 h of hypothermic preser-
vation, fatty livers pretreated with PEG conjugated to FITC
(PEG-FITC) or saline were washed out via the portal vein
with 20mL of Ringer lactate solution containing fluorescent
dyes. The fluorescent dyes were diluted in the washout liquid
and injected to the preserved fatty liver at the following final
concentrations: Hoechst 33342 trihydrochloride (12mg/kg
body weight, Invitrogen, H3570) for DNA-nuclei staining
and rhodamine 123 (0.11mg/kg body weight, Sigma, R8004)
for mitochondrial membrane potential staining. Fatty livers
were then carefully sectioned (0.5 cm3 fragments) and the
internal side of the liver was exposed on the glass coverslip
mounted on the stage of a Leica TCS SP5 resonant scan
multiphoton confocal microscope (Leica Microsystems Hei-
delberg GmbH) equipped with a HCX IR APO L 25x water
immersion objective (Numerical Aperture 0.95), scanner
at 400 lines/s, and a near infrared Titanium:Saphire laser
(MaiTai, SpectraPhysics) for two-photon excitation running
at 800 nm. Images were acquired with resonant scan at
8000 lines/second. Two-photon excitation was performed
at 800 nm and emission of the different fluorescent dyes
was captured at the following wavelength ranges: PEG-
FITC (400–550 nm), Hoechst 33342 (400–470 nm), and rho-
damine 123 (500–550 nm).
2.7. Vascular Resistance. Vascular resistance was defined as
the ratio of portal venous pressure which was maintained at
12mmHg during the reperfusion to flow rate and expressed
in mmHg/min per gram of liver/mL. Perfusion flow rate was
assessed continuously throughout the reperfusion period and
expressed as mL/min per gram of liver.
2.8. Western Blotting Technique. Liver tissue was homog-
enized in HEPES buffer and proteins were separated by
SDS-PAGE and transferred to PVDF membranes. Then,
membranes were immunoblotted over night at 4∘C using
the following antibodies: anti-p-AMPK𝛼 (Thr172, #2535),
anti-AMPK𝛼 (#2603), anti-p-SAPK/JNK (Thr183/Tyr185),
anti-p-p38 MAP kinase (Thr180/Tyr182, #9211), and anti-p-
p44/42 MAPK (Erk1/2, Thr202/Tyr204, #9101); the above
antibodies were all purchased from Cell Signaling (Danvers,
MA); anti-eNOS (610296) was purshased form Transduction
Laboratories (Lexington KY) and anti-b-actin (A5316) was
purshased from Sigma Chemical (St. Louis, MO, USA). After
washing, bound antibody was detected after incubation for
1 h at room temperature with the corresponding secondary
antibody linked to horseradish peroxidase. Bound complexes
were detected and quantified by scanning densitometry.
2.9. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism version 4.02 for Windows (GraphPad
Software). Quantitative data are reported as mean ± SEM
and statistical comparison was performed with analysis of
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Figure 1: Hepatic andmitochondrial injuries after cold ischemia. PEG 35 administration decreases aspartate aminotransferase (AST) (a) and
alanine aminotransferase (ALT) levels (b) after 24 h of cold storage. Confocal microscopy of mitochondrial membrane potential stained with
rhodamine 123 (green) after cold storage: mitochondrial depolarization occurs after preservation (c); however, in rats pretreated with PEG 35
conjugated to FITC, we observed bright punctate fluorescence showing polarized mitochondria (d). No PEG fluorescence has been detected
in liver sinusoids, neither in hepatocytes nor bound to cell membrane (d). Ctr 1: anaesthesia and laparotomy; UW: livers preserved in UW
preservation solution for 24 hours at 4∘C; PEG 35: Zucker obese rats treated intravenously with PEG 35 at 10mg/kg and steatotic livers were
then subjected to 24 h cold ischemia. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 1; #𝑝 < 0.05 versus UW.
variance, followed by Tukey tests. An associated probability
of 𝑝 < 0.05 was considered to be significant.
3. Results
3.1. Effect of Intravenous PEG 35 on Cold Storage of Steatotic
Rat Livers. To investigate the protective effect of intra-
venous PEG 35 treatment on liver preservation, we measured
transaminases levels in the effluent of washout liquid after
24 h of cold storage. As shown in Figures 1(a) and 1(b), liver
preservation resulted in increased AST/ALT levels versus
control group and the intravenous administration of PEG
35 at 10mg/kg decreased significantly transaminases release
indicating substantially less hepatocellular damage. Also, we
exploredmitochondrial polarization after fatty liver preserva-
tion using rhodamine 123 vital dye. In livers pretreated with
PEG 35, we observed bright punctate fluorescence standing
for the cells with polarized mitochondria. By contrast, in
nontreated livers, we observed a cloudy diffuse cytosolic
fluorescence standing for cells with depolarized mitochon-
dria (Figures 1(c) and 1(d)). Moreover, our result shows that
when obese rats were treated with PEG-FITC, no significant
PEG fluorescence was detected in liver sinusoids neither into
hepatocytes or other liver cells nor bound to cell membrane
(Figure 1(d)).
3.2. Effect of Intravenous PEG 35 Administration on Fatty
Liver Injury after Ischemia Reperfusion. In the following, we
evaluated the reperfusion injury after 2 hours of ex vivo
perfusion at 37∘C (Protocol 2). We observed a significant
decrease in transaminases levels in the perfusate from rats
pretreated with PEG 35 when compared to the untreated
ones (Figures 2(a) and 2(b)). Moreover, the evaluation of
mitochondrial damage, measured by GLDH activity, showed
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Figure 2: Hepatic and mitochondrial injuries after cold ischemia and reperfusion. PEG 35 administration decreases aspartate aminotrans-
ferase (AST) (a), alanine aminotransferase (ALT) (b), and glutamate dehydrogenase (GLDH) levels after 2 hours of ex vivo perfusion. Ctr
2: liver procurement and ex vivo perfusion; UW: livers preserved in UW preservation solution for 24 h at 4∘C and then subjected to 2 h of
normothermic ex vivo perfusion; PEG 35: rats treated intravenously with PEG 35 (10mg/kg) and then subjected to 24 h cold ischemia followed
by 2 h of normothermic ex vivo perfusion. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 2; #𝑝 < 0.05 versus UW.
significant decreases when rats were pretreated with PEG 35
(Figure 2(c)).
Steatotic livers present fat accumulation in the cytoplasm
of the hepatocytes which causes disturbance of the sinusoidal
flow during reperfusion [2, 16]. Given that, we explored
vascular resistance and endothelial nitric oxide synthase
(eNOS) activation after reperfusion. Figure 3(a) shows that
eNOS protein expression decreased after 2 h of ex vivo
perfusion in UW compared to control group. In contrast,
pretreatment with PEG 35 clearly induced eNOS expression
which was concomitant with decreased vascular resistance
(Figure 3(b)).
Next, we explored whether the hepatoprotective effect of
PEG 35 could be attributed to well-known cell signaling path-
ways associated with IRI such as adenosine monophosphate
activated protein kinase (AMPK) and protein kinase B (Akt).
As shown in Figure 4(a), liver preservation followed by 2
hours of ex vivo perfusion promoted Akt phosphorylation,
which was further enhanced when rats were pretreated with
PEG 35. Regarding AMPK, PEG 35 administration prior to
liver procurement induced a significant activation in AMPK
in comparison to non-PEG 35-treated rats (Figure 4(b)).
It is well known that mitogen activated protein kinase
(MAPK) signaling pathway regulates inflammation and cell
survival during IRI [17, 18].We therefore assessed the possible
involvement of MAPK regulation in the protective effect of
PEG 35. As indicated in Figure 5, all MAP kinases (p-p38,
p-JNK, and p-Erk) levels were increased at 2 h reperfusion.
A significant reduction in p-p38 activation was evident after
PEG 35 treatment (Figure 5(a)). On the contrary, no changes
for JNK and Erk activity were found (Figures 5(b) and 5(c),
resp.).
4. Discussion
The beneficial effects of PEG in tissue injury are well doc-
umented [5, 12–14, 19]. However, because PEG molecules
are not absorbed in the gastrointestinal tracts, their use
against ischemic damage was limited to their addition to
preservation solutions as oncotic agents. The present study
was thus designed to investigate if the intravenous PEG 35
administration by a unique and nontoxic dose of 10mg/kg
could protect steatotic liver grafts against the deleterious
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Figure 3: Effects of PEG 35 on eNOS activation and vascular resistance. PEG 35 pretreatment activates eNOS and decreases vascular
resistance: densitometric analysis of eNOS/𝛽-actin (a) and vascular resistance (b) after 120min of normothermic reperfusion. Ctr 2: liver
procurement and ex vivo perfusion; UW: livers preserved in UW preservation solution for 24 h at 4∘C and then subjected to 2 h of
normothermic ex vivo perfusion; PEG 35: rats treated intravenously with PEG 35 (10mg/kg) and then subjected to 24 h cold ischemia followed
by 2 h of normothermic ex vivo perfusion. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 2; #𝑝 < 0.05 versus UW.
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Figure 4: Effects of PEG 35 on Akt and AMPK. PEG 35 administration activates Akt and AMPK: densitometric analysis of phosphorylated
Akt/total Akt (a) and phosphorylated AMPK/total AMPK (b). Ctr 2: liver procurement and ex vivo perfusion; UW: livers preserved in UW
preservation solution for 24 h at 4∘C and then subjected to 2 h of normothermic ex vivo perfusion; PEG 35: rats treated intravenously with
PEG 35 (10mg/kg) and then subjected to 24 h cold ischemia followed by 2 h of normothermic ex vivo perfusion. Data represent mean ± SEM.
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effects of cold storage and the subsequent reperfusion. Our
data demonstrated that pretreatment of rats with PEG 35
lessened liver injury associated with ischemia reperfusion.
In our study, we have used the isolated perfused rat
liver (IPRL) model, a widely used and appreciated method
to assess cellular injury and liver function in an isolated
setting. In comparison to other in vitro models, the IPRL-
model does have considerable advantages, such as the use
of the entire intact organ instead of only single cells or
several layers of cells (i.e., isolated hepatocytes or the liver
slice model) and an intact cellular architecture. Furthermore,
the use of an acellular perfusion solution (Krebs solution)
prevents alloreactivity and permits a conclusive focus on
IRI effects. Regarding liver transplantation, IPRL model
presents the advantages of minimizing the use of laboratory
animals as well as the suppression of the immunological
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Figure 5: Effect of PEG 35 on MAPKs. PEG 35 reduces p38-MAPK activation whereas it has no effect on JNK and ERK phosphorylation.
Densitometric analysis of phosphorylated p38/𝛽-actin (a), phosphorylated JNK/𝛽-actin (b), and phosphorylated ERK/𝛽-actin (c). Ctr 2:
liver procurement and ex vivo perfusion; UW: livers preserved in UW preservation solution for 24 h at 4∘C and then subjected to 2 h of
normothermic ex vivo perfusion; PEG 35: rats treated intravenously with PEG 35 (10mg/kg) and then subjected to 24 h cold ischemia followed
by 2 h of normothermic ex vivo perfusion. Data represent mean ± SEM. ∗𝑝 < 0.05 versus Ctr 2; #𝑝 < 0.05 versus UW.
reactions and the influences of other organs occurring during
transplantation. The disadvantage of the IPRL-model is the
duration of reperfusion, which is limited to 90–120 minutes
and the fact that it remains an in vitro tool that merely
simulates the initial phase after liver transplantation. In this
sense IPRL model could be considered as a pre-screening
model before liver transplantation especially in ischemia
reperfusion research [20, 21].
In contrast to the current pharmacological strategies used
against IRI, PEG administration presents the advantages of
being amultitarget strategy. In fact, IRI is amultifactorial dis-
ease including oxidative stress, inflammation, proteasome
activation, endoplasmic reticulum stress, mitochondrial
damage, and cytoskeleton alterations which lead to cell death
and organ dysfunction [22–24]. PEG has been associated
with the majority of these events as it has been shown that
PEG reduces reactive oxygen species, prevents cell death,
maintainsmitochondrial integrity, and reduces inflammation
and endoplasmic reticulum stress [12, 14, 19, 25, 26].
The half-life and biodistribution of the polymer and
consequently its activity mainly depend on its molecular
weight. Based on our experience in organ preservation, we
used PEGwith amolecular weight of 35 kDa. Indeed, we have
previously demonstrated that PEG 35 addition to washout
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solution protected the liver against reperfusion injuries [27].
Moreover, PEG 35 addition to IGL-1 preservation solution
protects kidney and liver grafts against ischemic damage
[7, 8, 28, 29]. PEG with a molecular weight of 20 kDa has
also been used as an additive to HTK and SCOT preservation
solutions and was associated with protective effects against
IRI in pancreas [30], kidney [8], intestine [26], and liver grafts
[31]. In addition, PEG20 has been shown to protect against
cardiomyocyte apoptosis induced by hypoxia [12]. However,
PEG 35 was more effective than PEG20 in protecting porcine
proximal tubular epithelial cell line against cold storage at the
same doses used [32].
Mitochondrial protection is essential for graft survival
after transplantation [33]. Thus, we further explored mito-
chondrial depolarization after cold preservation and we evi-
denced that PEG 35 prevented fatty liver mitochondria depo-
larization after prolonged cold ischemia. Also, mitochondrial
injury was lessened after liver reperfusion as indicated by
the decrease in GLDH release. These results are in accor-
dance with previous published data showing that PEG 2 kDa
improved mitochondrial function in vitro and in vivo after
acute spinal cord injury [25]. Moreover, PEG of 4 kDa inhib-
ited mitochondrial pore transition (MPT) and cytochrome
C release in rat liver mitochondria [34]. Also, PEG (1.5 and
2 kDa) was able to cross the cytoplasmic membrane and
directly interact with neuronal mitochondria to preserve its
structure and restore function [14]. Interestingly, PEG with
higher molecular weight (4 kDa) failed to exert significant
improvement in neuronal injured mitochondria indicating
that PEG-mediated mitochondrial protection is dependent
on the size of PEG [14]. In our study, we did not detect any
PEG fluorescence after cold storage in liver sinusoids, neither
in hepatocytes nor bound to cell membrane. In this sense,
the mechanism by which PEG 35 decreases mitochondrial
damage and exerts its protective effects needs more profound
investigation.
Our results show that PEG35 activated eNOS, the enzyme
responsible for nitric oxide (NO) generation, and conse-
quently decreased vascular resistance.This could also explain
the protective mechanism of PEG toward mitochondria as it
has been showed that NO protects rat hepatocytes against
reperfusion injury through the inhibition of MPT [35].
Previous study from Bertuglia et al. has shown that PEG
15–20 kDa reduced vasoconstriction and the altered capillary
perfusion after ischemia reperfusion [36]. However, in that
case, the decreased vascular resistance of PEG were not
mediated by eNOS activation [36].
In order to explore whether the beneficial effects of
PEG 35 are associated with other well-known cell signaling
pathways involved in IRI, we further evaluated the acti-
vation of AMPK and Akt and the regulation of MAPKs.
AMPK is a metabolic fuel gauge and energy regulator
activated during ischemia in order to induce an energy-
saving state preventing thus the lactate accumulation and
cell death [37–39]. Here, we showed that PEG 35 enhanced
AMPK levels after reperfusion, which could contribute to
assuring energy levels sufficient to cell survival. Another
cytoprotective marker is Akt, a serine-threonine protein
kinase that is linked to cell survival during reperfusion
[40–42]. Data reported here revealed that PEG 35 increased
Akt levels, as similarly observed with PEG 20 in cardiac
myocyte submitted to IRI [12]. Regarding MAPKs signalling,
we observed that PEG 35 was capable of preventing p38
activation, while no changes were found on JNK and ERK
pathways. The data reported here are consistent with pre-
viously reported works showing that the inhibition of p38
prevented preservation-induced graft injury and improved
the outcome of liver transplantation [43–45]. Other studies
as well reported that PEG 35 decreased p38 activation while
it activated JNK in cold stored porcine proximal tubular cell
line [32].
The rationale of PEG 35 intravenous administration was
to induce a pharmacological preconditioning against the
subsequent cold storage and reperfusion injury. PEG presents
the advantages of being safe andmultifactorial agent andmay
constitute a novel strategy to increase liver graft preservation.
This could be relevant in clinical situation of brain-dead
donors or steatotic livers, both being risk factors in liver
transplantation. Until now, PEG has been used clinically
for ischemia reperfusion purpose as additive to preservation
solution due to its oncotic properties. In this study, we
used UW solution which contains hydroxyethyl starch as an
oncotic support in order to demonstrate that the protective
mechanisms of PEG are not only related to its oncotic effect,
but also to other properties such as the preservation of
mitochondria and the induction of protective cell signaling
pathway (eNOS, Akt, and AMPK). In a previous study we
have shown that PEG addition to rinse solution protected
preserved liver against the subsequent reperfusion injury
(PEG postconditioning). Interestingly, when liver grafts were
preserved in IGL-1 solution which contains PEG 35, the
rinse solution does not show any additional protective effect
[46]. In this sense, PEG pre- and postconditioning would be
considered as a safe and protective strategy applicable to all
preservation solutions.
5. Conclusions
PEG 35 represents a potential pharmacological agent for pre-
venting the deleterious effects of cold IRI and may constitute
a novel clinical strategy to increase liver graft preservation,
especially for “marginal” organs.
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